ArticlePulmonary circulation2026
Prognostic Value of Right Atrial Adverse Remodeling in Patients With Pulmonary Arterial Hypertension.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of right atrial (RA) structure helps monitor right heart (RH) function, critical for prognosis in pulmonary arterial hypertension (PAH). This study aims to assess the prognostic value of RA adverse remodeling (RAAR) with targeted therapy in PAH. Patients diagnosed with PAH between June 2013 and June 2024 were prospectively recruited. Right atrial reverse remodeling (RAAR) was defined by the relative change in right atrial diameter (RAD) on 1-year follow-up echocardiography (ECHO). RAAR was defined as a RAD decrease of < 13% or any increase from baseline, as determined by receiver operating characteristic curve analysis. The primary composite endpoint included heart failure-related readmission, all-cause mortality, and lung transplantation. Of 240 patients enrolled, 234 completed 1-year follow-up, with a median follow-up duration of 37.5 months (interquartile range: 23.3-57.5 months). RAAR was observed in 168 patients (71.8%), and baseline RAD was its sole independent predictor (OR 0.941,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.